{
  "url": "https://finance.yahoo.com/news/beamtree-holdings-full-2025-earnings-212733611.html",
  "authorsByline": "Simply Wall St",
  "articleId": "eb1ee27e7a0a44688a604ed30f4792c5",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-29T21:27:33+00:00",
  "addDate": "2025-08-29T21:56:09.594453+00:00",
  "refreshDate": "2025-08-29T21:56:09.594455+00:00",
  "score": 1.0,
  "title": "Beamtree Holdings Full Year 2025 Earnings: Revenues Miss Expectations",
  "description": "Beamtree Holdings ( ASX:BMT ) Full Year 2025 Results Key Financial Results Revenue: AU$25.0m (down 9.4% from FY 2024...",
  "content": "AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\n\nLooking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia.\n\nThe company's shares are down 9.6% from a week ago.\n\nYou should learn about the 2 warning signs we've spotted with Beamtree Holdings.\n\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n\n\n\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/0382D052-E07E-40E3-9A86-CF7779C23F3A?blueprint=4025765&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4025765&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
    "https://simplywall.st/markets/au/healthcare/healthtech?blueprint=4025765&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
    "https://simplywall.st/company/id/0382D052-E07E-40E3-9A86-CF7779C23F3A/future?blueprint=4025765&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/BMT.AX"
  ],
  "labels": [
    {
      "name": "Roundup"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Simply Wall St",
      "weight": 0.085692555
    },
    {
      "name": "analyst forecasts",
      "weight": 0.07802955
    },
    {
      "name": "historical data",
      "weight": 0.07374283
    },
    {
      "name": "Beamtree Holdings",
      "weight": 0.07113422
    },
    {
      "name": "fundamental data",
      "weight": 0.06907635
    },
    {
      "name": "early diagnostics",
      "weight": 0.06569731
    },
    {
      "name": "financial advice",
      "weight": 0.064210206
    },
    {
      "name": "Healthcare Services",
      "weight": 0.063933656
    },
    {
      "name": "Revenues",
      "weight": 0.06392145
    },
    {
      "name": "revenue",
      "weight": 0.06392145
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.9658203125
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.96142578125
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.94970703125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.63916015625
    },
    {
      "name": "/Health/Medical Facilities & Services/Other",
      "score": 0.392822265625
    }
  ],
  "sentiment": {
    "positive": 0.04473468,
    "negative": 0.6926294,
    "neutral": 0.26263586
  },
  "summary": "Begantree Holdings, a company that focuses on early diagnostics and drug discovery, has reported a 9.6% drop in its shares compared to the expected growth of 20% for the next three years. The company's revenue is forecast to grow 20% p.a. on average, compared to a 20% forecast for the Healthcare Services industry in Australia. This article discusses two warning signs for the company.",
  "shortSummary": "Beachtree Holdings' full-year earnings forecast for 2025 are disappointing, with forecasts for 20% growth compared to 20% for the previous three years.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "390e0c1bd0914073ba98b332be20e426",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/markets/au/healthcare/healthtech?blueprint=4025765&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
      "text": "Over the last 7 days, the Healthtech industry has dropped 2.2%, driven by Pro Medicus declining 2.5%. In contrast, Artrya has gained 6.5%. This takes the industry's 12 month performance to a gain of 94%. Earnings are forecast to grow by 22% annually.\nHas the Australian Healthtech Industry valuation changed over the past few years?\n| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |\n|---|---|---|---|---|---|---|\n| Fri, 29 Aug 2025 | AU$32.9b | AU$570.2m | -AU$27,869,467.17 | 145.5x | -1181x | 57.7x |\n| Sun, 27 Jul 2025 | AU$35.0b | AU$525.7m | -AU$41,723,885.80 | 184.5x | -837.9x | 66.5x |\n| Tue, 24 Jun 2025 | AU$29.7b | AU$527.9m | -AU$42,154,934.61 | 154.6x | -704x | 56.2x |\n| Thu, 22 May 2025 | AU$30.8b | AU$526.7m | -AU$41,624,499.08 | 160x | -739.2x | 58.4x |\n| Sat, 19 Apr 2025 | AU$22.8b | AU$527.9m | -AU$42,059,250.49 | 119.6x | -541.4x | 43.1x |\n| Mon, 17 Mar 2025 | AU$25.7b | AU$527.8m | -AU$41,427,446.76 | 134.9x | -621.2x | 48.8x |\n| Wed, 12 Feb 2025 | AU$31.9b | AU$585.7m | -AU$63,761,840.18 | 118.4x | -499.8x | 54.4x |\n| Fri, 10 Jan 2025 | AU$29.4b | AU$587.1m | -AU$64,183,783.71 | 153.3x | -458.1x | 50.1x |\n| Sun, 08 Dec 2024 | AU$29.3b | AU$585.4m | -AU$63,733,098.78 | 219.2x | -460.5x | 50.1x |\n| Tue, 05 Nov 2024 | AU$21.7b | AU$582.0m | -AU$63,097,841.32 | 174x | -343.4x | 37.2x |\n| Thu, 03 Oct 2024 | AU$20.3b | AU$577.3m | -AU$61,850,805.92 | 228x | -327.5x | 35.1x |\n| Sat, 31 Aug 2024 | AU$17.1b | AU$577.1m | -AU$56,698,163.78 | 190.2x | -302x | 29.7x |\n| Mon, 29 Jul 2024 | AU$15.6b | AU$536.7m | -AU$82,725,809.88 | 113.9x | -188.6x | 29.1x |\n| Wed, 26 Jun 2024 | AU$16.3b | AU$532.9m | -AU$81,579,134.61 | 118.8x | -200.3x | 30.7x |\n| Fri, 24 May 2024 | AU$13.5b | AU$533.7m | -AU$81,913,736.31 | 99.4x | -164.3x | 25.2x |\n| Sun, 21 Apr 2024 | AU$12.4b | AU$571.4m | -AU$90,955,027.16 | 90x | -135.9x | 21.6x |\n| Tue, 19 Mar 2024 | AU$12.1b | AU$571.4m | -AU$103,107,735.79 | 86.6x | -117.1x | 21.1x |\n| Thu, 15 Feb 2024 | AU$12.9b | AU$531.7m | -AU$133,741,293.14 | 111x | -96.8x | 24.4x |\n| Sat, 13 Jan 2024 | AU$11.8b | AU$528.1m | -AU$140,091,938.00 | 104.4x | -84.5x | 22.4x |\n| Mon, 11 Dec 2023 | AU$11.0b | AU$528.0m | -AU$106,676,208.00 | 98.8x | -103.4x | 20.9x |\n| Wed, 08 Nov 2023 | AU$10.3b | AU$527.0m | -AU$107,658,833.00 | 95.9x | -96.1x | 19.6x |\n| Fri, 06 Oct 2023 | AU$10.4b | AU$528.5m | -AU$107,765,825.00 | 93.9x | -96.7x | 19.7x |\n| Sun, 03 Sep 2023 | AU$9.3b | AU$532.5m | -AU$113,521,390.00 | 86.9x | -82.3x | 17.5x |\n| Tue, 01 Aug 2023 | AU$8.9b | AU$500.2m | -AU$153,178,812.00 | 94.1x | -58.3x | 17.9x |\n| Thu, 29 Jun 2023 | AU$8.4b | AU$500.5m | -AU$153,015,191.00 | 93.7x | -55.1x | 16.8x |\n| Sat, 27 May 2023 | AU$7.9b | AU$500.8m | -AU$143,050,523.00 | 86.5x | -55.1x | 15.7x |\n| Mon, 24 Apr 2023 | AU$8.1b | AU$493.8m | -AU$145,363,794.00 | 88.3x | -55.9x | 16.4x |\n| Wed, 22 Mar 2023 | AU$8.2b | AU$493.2m | -AU$144,628,456.00 | 89.9x | -56.4x | 16.5x |\n| Fri, 17 Feb 2023 | AU$8.3b | AU$453.6m | -AU$144,823,307.00 | 83.3x | -57.3x | 18.3x |\n| Sun, 15 Jan 2023 | AU$7.8b | AU$440.0m | -AU$154,768,548.00 | 85.5x | -50.4x | 17.7x |\n| Tue, 13 Dec 2022 | AU$7.6b | AU$444.7m | -AU$156,348,041.00 | 81.2x | -48.4x | 17x |\n| Thu, 10 Nov 2022 | AU$7.1b | AU$441.4m | -AU$157,210,090.00 | 75.9x | -45.1x | 16.1x |\n| Sat, 08 Oct 2022 | AU$7.2b | AU$439.7m | -AU$155,704,505.00 | 79x | -46.1x | 16.3x |\n| Mon, 05 Sep 2022 | AU$7.2b | AU$433.8m | -AU$155,943,991.00 | 74.1x | -46x | 16.5x |\n-46x\nWhich industries have driven the changes within the Australian Healthcare industry?\n| AU Market | -0.35% | |\n| Healthcare | -2.50% | |\n| Healthtech | -2.22% | |\n| Healthtech | -2.22% |\nWhich companies have driven the market over the last 7 days?\n| Company | Last Price | 7D | 1Y | Valuation | |\n|---|---|---|---|---|---|\n| AYA Artrya | AU$2.13 | 6.5% +AU$19.8m | 634.5% | PS8949x | |\n| 4DX 4DMedical | AU$0.57 | 6.5% +AU$16.3m | 29.5% | PS45.3x | |\n| ONE Oneview Healthcare | AU$0.23 | 7.1% +AU$11.5m | -43.8% | PS8.3x | |\n| SHG Singular Health Group | AU$0.35 | 11.1% +AU$10.7m | 337.5% | PS121.4x | |\n| BB1 BlinkLab | AU$0.57 | 17.5% +AU$10.6m | 165.1% | PS190.1x |"
    },
    {
      "url": "https://simplywall.st/company/id/0382D052-E07E-40E3-9A86-CF7779C23F3A?blueprint=4025765&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Beamtree Holdings (BMT) Stock Overview\nProvides artificial intelligence-based decision support software and data insight solutions, and other software services to the healthcare industry in Australia and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 4/6 |\n| Future Growth | 2/6 |\n| Past Performance | 0/6 |\n| Financial Health | 4/6 |\n| Dividends | 0/6 |\nBMT Community Fair Values\nSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nBeamtree Holdings Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | AU$0.23 |\n| 52 Week High | AU$0.38 |\n| 52 Week Low | AU$0.17 |\n| Beta | 1.74 |\n| 1 Month Change | -11.32% |\n| 3 Month Change | -17.54% |\n| 1 Year Change | -25.40% |\n| 3 Year Change | -24.19% |\n| 5 Year Change | -6.00% |\n| Change since IPO | 30.56% |\nRecent News & Updates\nBeamtree Holdings Limited (ASX:BMT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry\nMay 16Benign Growth For Beamtree Holdings Limited (ASX:BMT) Underpins Stock's 28% Plummet\nMar 10Recent updates\nBeamtree Holdings Limited (ASX:BMT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry\nMay 16Benign Growth For Beamtree Holdings Limited (ASX:BMT) Underpins Stock's 28% Plummet\nMar 10Lacklustre Performance Is Driving Beamtree Holdings Limited's (ASX:BMT) 27% Price Drop\nNov 01A Piece Of The Puzzle Missing From Beamtree Holdings Limited's (ASX:BMT) 40% Share Price Climb\nAug 28A Piece Of The Puzzle Missing From Beamtree Holdings Limited's (ASX:BMT) 31% Share Price Climb\nMay 10Beamtree Holdings Limited (ASX:BMT) Might Not Be As Mispriced As It Looks\nJul 27Is Now The Time To Look At Buying Beamtree Holdings Limited (ASX:BMT)?\nApr 05Estimating The Intrinsic Value Of Beamtree Holdings Limited (ASX:BMT)\nFeb 06A Look At The Fair Value Of PKS Holdings Limited (ASX:PKS)\nFeb 05Can PKS Holdings Limited (ASX:PKS) Improve Its Returns?\nJan 01If You Had Bought PKS Holdings (ASX:PKS) Stock A Year Ago, You Could Pocket A 115% Gain Today\nNov 23Shareholder Returns\n| BMT | AU Healthcare Services | AU Market | |\n|---|---|---|---|\n| 7D | -9.6% | -2.2% | -0.3% |\n| 1Y | -25.4% | 93.9% | 11.0% |\nReturn vs Industry: BMT underperformed the Australian Healthcare Services industry which returned 93.9% over the past year.\nReturn vs Market: BMT underperformed the Australian Market which returned 11% over the past year.\nPrice Volatility\n| BMT volatility | |\n|---|---|\n| BMT Average Weekly Movement | 8.9% |\n| Healthcare Services Industry Average Movement | 10.1% |\n| Market Average Movement | 8.9% |\n| 10% most volatile stocks in AU Market | 19.3% |\n| 10% least volatile stocks in AU Market | 3.5% |\nStable Share Price: BMT has not had significant price volatility in the past 3 months compared to the Australian market.\nVolatility Over Time: BMT's weekly volatility (9%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1996 | 97 | Marek Stepniak | beamtree.com.au |\nBeamtree Holdings Limited provides artificial intelligence-based decision support software and data insight solutions, and other software services to the healthcare industry in Australia and internationally. It operates through four segments: Diagnostic; Clinical Decision Support; Coding & Data Quality Assurance; and Analytics and Knowledge Networks. The company offers Activity BarCoding, and on-premise solution that captures customized data across organizations to support various operations; Ainsoff Deterioration Index, an application that enables acuity monitoring across the whole organization; operational services in health and social services data analytics; and clinical coding, auditing, education and training services.\nBeamtree Holdings Limited Fundamentals Summary\n| BMT fundamental statistics | |\n|---|---|\n| Market cap | AU$68.28m |\n| Earnings (TTM) | -AU$6.20m |\n| Revenue (TTM) | AU$25.00m |\nIs BMT overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| BMT income statement (TTM) | |\n|---|---|\n| Revenue | AU$25.00m |\n| Cost of Revenue | AU$20.60m |\n| Gross Profit | AU$4.40m |\n| Other Expenses | AU$10.60m |\n| Earnings | -AU$6.20m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -0.021 |\n| Gross Margin | 17.60% |\n| Net Profit Margin | -24.80% |\n| Debt/Equity Ratio | 5.5% |\nHow did BMT perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 18:41 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nBeamtree Holdings Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Jules Cooper | Shaw and Partners Limited |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4025765&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nCosmo Pharmaceuticals\nMarket Cap: US$994.6m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\n-21.1%\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$19.2m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$2.75\n7D\n-15.4%\n1Y\n-82.0%\nImmunoPrecise Antibodies\nMarket Cap: US$114.9m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$2.37\n7D\n-25.9%\n1Y\n213.9%\nCareCloud\nMarket Cap: US$157.0m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$3.78\n7D\n39.0%\n1Y\n38.0%\nGeneDx Holdings\nMarket Cap: US$3.7b\nA genomics company, provides genetic testing services.\nWGS\nUS$129.49\n7D\n0.6%\n1Y\n305.4%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.48\n7D\n-2.2%\n1Y\n3.6%\nSpectral AI\nMarket Cap: US$53.2m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$1.93\n7D\n-7.7%\n1Y\n35.0%\nRevenio Group Oyj\nMarket Cap: US$639.8m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.5b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$71.79\n7D\n4.6%\n1Y\n11.0%\nSimulations Plus\nMarket Cap: US$286.2m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.17\n7D\n-2.7%\n1Y\n-60.9%\nRakovina Therapeutics\nMarket Cap: US$10.6m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.30\n7D\n-18.6%\n1Y\nn/a\nNano-X Imaging\nMarket Cap: US$251.9m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$3.88\n7D\n-3.2%\n1Y\n-38.2%\nCeriBell\nMarket Cap: US$438.9m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$11.83\n7D\n-1.9%\n1Y\nn/a\nGuardant Health\nMarket Cap: US$8.0b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$67.42\n7D\n9.8%\n1Y\n163.6%\nHeartSciences\nMarket Cap: US$12.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.41\n7D\n-6.6%\n1Y\n0.3%\nPerimeter Medical Imaging AI\nMarket Cap: US$23.8m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.16\n7D\n-8.5%\n1Y\n-31.6%\nOmniAb\nMarket Cap: US$197.5m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.64\n7D\n-8.9%\n1Y\n-61.6%\nNeuroOne Medical Technologies\nMarket Cap: US$36.9m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.76\n7D\n-2.6%\n1Y\n-4.0%\nXtalPi Holdings\nMarket Cap: US$41.4b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.40\n7D\n16.7%\n1Y\nn/a\nBioXcel Therapeutics\nMarket Cap: US$59.7m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$4.05\n7D\n-18.7%\n1Y\n-58.8%\nLantheus Holdings\nMarket Cap: US$3.9b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$55.50\n7D\n-6.2%\n1Y\n-47.0%\nAcarix\nMarket Cap: US$314.5m\nA medical device company, develops solutions for rapid AI-based coronary artery disease rule-out.\nACIX.F\nUS$0.035\n7D\n-4.8%\n1Y\n9.0%\nHealwell AI\nMarket Cap: US$359.4m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.95\n7D\n-4.1%\n1Y\n-31.7%\nAbsci\nMarket Cap: US$369.3m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.39\n7D\n-9.1%\n1Y\n-45.7%\nPersonalis\nMarket Cap: US$423.9m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.78\n7D\n2.6%\n1Y\n-17.6%\nVeradigm\nMarket Cap: US$837.3m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.90\n7D\n1.0%\n1Y\n-50.8%"
    },
    {
      "url": "https://simplywall.st/company/id/0382D052-E07E-40E3-9A86-CF7779C23F3A/future?blueprint=4025765&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Beamtree Holdings Future Growth\nFuture criteria checks 2/6\nBeamtree Holdings is forecast to grow earnings and revenue by 63.2% and 20.1% per annum respectively. EPS is expected to grow by 79.9% per annum. Return on equity is forecast to be -2.1% in 3 years.\nKey information\n63.2%\nEarnings growth rate\n79.93%\nEPS growth rate\n| Healthcare Services earnings growth | 22.5% |\n| Revenue growth rate | 20.1% |\n| Future return on equity | -2.13% |\n| Analyst coverage | Low |\n| Last updated | 28 Aug 2025 |\nRecent future growth updates\nRecent updates\nBeamtree Holdings Limited (ASX:BMT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry\nMay 16Benign Growth For Beamtree Holdings Limited (ASX:BMT) Underpins Stock's 28% Plummet\nMar 10Lacklustre Performance Is Driving Beamtree Holdings Limited's (ASX:BMT) 27% Price Drop\nNov 01A Piece Of The Puzzle Missing From Beamtree Holdings Limited's (ASX:BMT) 40% Share Price Climb\nAug 28A Piece Of The Puzzle Missing From Beamtree Holdings Limited's (ASX:BMT) 31% Share Price Climb\nMay 10Beamtree Holdings Limited (ASX:BMT) Might Not Be As Mispriced As It Looks\nJul 27Is Now The Time To Look At Buying Beamtree Holdings Limited (ASX:BMT)?\nApr 05Estimating The Intrinsic Value Of Beamtree Holdings Limited (ASX:BMT)\nFeb 06A Look At The Fair Value Of PKS Holdings Limited (ASX:PKS)\nFeb 05Can PKS Holdings Limited (ASX:PKS) Improve Its Returns?\nJan 01If You Had Bought PKS Holdings (ASX:PKS) Stock A Year Ago, You Could Pocket A 115% Gain Today\nNov 23Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 6/30/2028 | 49 | -1 | 2 | 8 | 1 |\n| 6/30/2027 | 39 | -3 | -1 | 4 | 1 |\n| 6/30/2026 | 31 | -5 | -2 | 2 | 1 |\n| 6/30/2025 | 25 | -6 | -2 | 1 | N/A |\n| 3/31/2025 | 27 | -6 | -2 | 1 | N/A |\n| 12/31/2024 | 29 | -5 | -2 | 2 | N/A |\n| 9/30/2024 | 28 | -5 | -3 | 1 | N/A |\n| 6/30/2024 | 28 | -5 | -5 | 0 | N/A |\n| 3/31/2024 | 26 | -5 | -5 | -1 | N/A |\n| 12/31/2023 | 25 | -6 | -5 | -2 | N/A |\n| 9/30/2023 | 24 | -6 | -4 | -1 | N/A |\n| 6/30/2023 | 23 | -7 | -2 | 1 | N/A |\n| 3/31/2023 | 21 | -7 | -2 | 1 | N/A |\n| 12/31/2022 | 20 | -7 | -1 | 0 | N/A |\n| 9/30/2022 | 18 | -6 | -3 | -1 | N/A |\n| 6/30/2022 | 17 | -4 | -5 | -2 | N/A |\n| 3/31/2022 | 14 | -3 | -6 | -2 | N/A |\n| 12/31/2021 | 12 | -2 | -6 | -2 | N/A |\n| 9/30/2021 | 10 | -1 | -4 | -1 | N/A |\n| 6/30/2021 | 8 | 0 | -3 | 0 | N/A |\n| 3/31/2021 | 7 | 0 | -2 | 0 | N/A |\n| 12/31/2020 | 6 | 0 | -1 | 1 | N/A |\n| 9/30/2020 | 5 | 0 | 0 | 1 | N/A |\n| 6/30/2020 | 4 | 0 | 0 | 1 | N/A |\n| 3/31/2020 | 3 | 0 | 0 | 0 | N/A |\n| 12/31/2019 | 2 | -1 | -1 | 0 | N/A |\n| 9/30/2019 | 1 | -1 | -1 | -1 | N/A |\n| 6/30/2019 | 0 | -1 | -1 | -1 | N/A |\n| 3/31/2019 | 1 | 0 | N/A | 0 | N/A |\n| 12/31/2018 | 2 | 1 | N/A | 1 | N/A |\n| 9/30/2018 | 3 | 1 | N/A | 2 | N/A |\n| 6/30/2018 | 4 | 2 | N/A | 2 | N/A |\n| 6/30/2017 | 3 | 3 | N/A | 1 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: BMT is forecast to remain unprofitable over the next 3 years.\nEarnings vs Market: BMT is forecast to remain unprofitable over the next 3 years.\nHigh Growth Earnings: BMT is forecast to remain unprofitable over the next 3 years.\nRevenue vs Market: BMT's revenue (20.1% per year) is forecast to grow faster than the Australian market (5.5% per year).\nHigh Growth Revenue: BMT's revenue (20.1% per year) is forecast to grow faster than 20% per year.\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: BMT is forecast to be unprofitable in 3 years.\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 18:41 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nBeamtree Holdings Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Jules Cooper | Shaw and Partners Limited |"
    }
  ],
  "argos_summary": "The article explains how AI is set to transform healthcare through better diagnostics, personalized medicine, operational efficiency, telemedicine and accelerated drug discovery, citing 20 AI\u2011driven companies under $10\u202fbn market cap. It projects a 20% annual revenue growth for these firms over the next three years, matching the Australian healthcare services growth rate, and uses Beamtree Holdings as a case study, noting its current underperformance, negative earnings and modest growth prospects. The piece highlights AI\u2019s potential to improve accuracy, access and affordability while warning of data privacy, bias and integration costs.",
  "argos_id": "SGULOLI7P"
}